← Back to all trials
No Longer Available
NCT00677313
Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Sponsor: Bristol-Myers Squibb
Summary
This is an expanded access designed to provide metreleptin for the treatment of diabetes mellitus and/or hypertriglyceridemia associated with lipodystrophy.
Eligibility Criteria
Inclusion Criteria:
\-
Exclusion Criteria:
\-
Source: ClinicalTrials.gov (NCT00677313). StuddyBuddy aggregates publicly available trial information.